Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclophosphamide + paclitaxel is a combination chemotherapy regimen consisting of two antineoplastic agents: cyclophosphamide, an alkylating agent that cross-links DNA and inhibits cancer cell replication, and paclitaxel, a taxane that stabilizes microtubules and prevents cell division. This combination is used primarily in the treatment of breast cancer, including early-stage or advanced/metastatic breast cancer. It is sometimes used as part of a larger multi-drug regimen (such as AC-T, which also includes doxorubicin), but cyclophosphamide + paclitaxel alone is also utilized in research and clinical practice for breast cancer and potentially other solid tumors. The drugs act through complementary mechanisms: cyclophosphamide damages DNA during the resting phase of the cell cycle, while paclitaxel disrupts cell division by inhibiting the breakdown of microtubules required for mitosis[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclophosphamide + paclitaxel.